Singapore, Feb. 25 -- Israel-based CollPlant Biotechnologies, a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, has announced the expansion of its distribution channels for its Vergenix STR product, in Europe and Asia.

VergenixSTR is based on the company's rhCollagen technology and is intended for the treatment of tendinopathy by promoting healing and repair of tendon injuries in a variety of tendons including the elbow tendon (for treatment of tennis elbow), rotator cuffs, patellar tendons, the Achilles tendon, and hand tendons.

Specifically, CollPlant recently signed distribution agreements for Vergenix...